BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Polaris Group readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Polaris Group's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04587830-2830@assetmemo.bio
DTSTAMP:20261121T010149Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pegargiminase: Phase 2 readout est. (NCT04587830)
DESCRIPTION:Pegargiminase\, phase 2.\nStudy: ADI-PEG 20 Plus Radiotherapy a
 nd Temozolomide in Subjects With Glioblastoma Multiforme\nEstimated primar
 y completion: 28 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pegargiminase#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04587830
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05842512-2830@assetmemo.bio
DTSTAMP:20261121T010149Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pegargiminase: Phase 2 readout est. (NCT05842512)
DESCRIPTION:Pegargiminase\, phase 2.\nStudy: Study of ADI-PEG 20 Versus Pla
 cebo in Subjects With NASH\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pegargiminase#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05842512
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317819-2830@assetmemo.bio
DTSTAMP:20261121T010149Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pegargiminase: Phase 3 readout est. (NCT05317819)
DESCRIPTION:Pegargiminase\, phase 3\, Hepatocellular Carcinoma.\nStudy: Stu
 dy of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and U
 nresectable Hepatocellular Carcinoma\nEstimated primary completion: Septem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegargimina
 se#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5317819
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
